Post-operative ocular inﬂammation is treated with topical steroids but with side effects. Nepafenac isan effective NSAID with minimal side effects. This study aims to compare effectiveness topical nepafenac0.1% (nepafenac) and prednisolone acetate 1% (prednisolone) post-pars plana vitrectomy (PPV) forrhegmatogenous retinal detachment (RRD). This is a prospective, single blind, randomized, single centerclinical study performed on December 2015 to May 2016 at dr. Cipto Mangunkusumo Hospital, Jakarta. Atotal of 46 eyes (n=46) with RRD underwent PPV were included and randomized to topical nepafenac (23eyes) or prednisolone 1% (23 eyes). The median of anterior chamber inflammation, scores of pain, centralmacular thickness (CMT), and intraocular pressure (IOP) were evaluated at day 1, followed by 1st, 2nd, and4th week post-surgery. Median anterior chamber inflammation was grade 2 (1-4) in prednisolone group andgrade 3 (0.5-4) in nepafenac group at day 1 (p>0.05). Number of cell of anterior chamber inflammation andpain perception were not significantly different between groups (p>0.05) on follow-up. At day 1, nepafenacand prednisolone groups showed median CMT of 206 μm (131-299) and 208 μm (129-451). At 4th week, meanCMT were 174.9±30.7μm in prednisolone and 185.5±50.1μm in nepafenac group (p>0.05). Post-operativetopical nepafenac was equal to prednisolone in reducing inflammation in eyes undergoing PPV. Nepafenaccould be an alternative for post-PPV in RRD.
|Journal||eJournal Kedokteran Indonesia|
|Publication status||Published - Apr 2019|